



+




+



PSA-DT

Quick Calculation Guide

**PSA-DT ≤ 10
months,
if ΔPSA ≥**



This is a patient education material/tool provided to you by Johnson and Johnson (Philippines), Inc.
This material is for the use of Philippine Healthcare Professionals only.
This material is for use with the PSA Quick Calculation Guide.

NP-ER-2022-001
Production Date: May 2022

Questions or comments or request for product insert/information?
Email us at Janssendrugsafety_Phil@its.jnj.com

Johnson & Johnson (Philippines), Inc.
Km. 14, Edison Road Merville,
City of Parañaque NCR,
Fourth District Philippines 1700

Johnson & Johnson
(PHILIPPINES), INC.

PROSTATE CANCER IS A PROGRESSIVE DISEASE,
AND IT'S IMPORTANT TO KEEP TRACK OF THE INDICATORS
THAT MEASURE ITS PROGRESS³

➤ TESTOSTERONE AT CASTRATION LEVELS

< 50 ng/dL or 1.7 nmol/L

➤ BIOCHEMICAL PROGRESSION

Three consecutive PSA increases at one week apart,
resulting in two 50% increases from PSA nadir, and
at least one PSA > 2 ng/mL.

➤ NO EVIDENCE OF DISTANT METASTASES


by conventional methods (thorax, abdomen,
pelvis CTs, bone; scintigraphy).

PSA-DT THE IMPORTANCE OF PSA PROGRESSION

Definition of high-risk patient

- In nmCRPC, the shorter the PSA doubling time (PSA-DT), the greater the risk of metastases.⁴

Relative risk for bone metastasis or death



Patients with PSA-DT ≤ 10 are considered high-risk patients¹


Adapted from Smith MR, et al. Denosumab and Bone Metastasis-Free Survival in Men With Nonmetastatic Castration Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time. J Clin Oncol. 2013;31:3800–6.

PSA-DT HOW IS IT CALCULATED?

Between two consecutive measurements

PSA-DT: measures the exponential increase in serum PSA over time.¹

PSA progression



Calculate PSA-DT:⁶

$$\text{PSA-DT} = \frac{\ln(\text{PSAx}) - \ln(\text{PSA1})}{\text{Time between PSA1 and PSAx}}$$

x = PSA measurement considered for the calculation


- **PSA-DT** change between the first and second PSA measurements is 9.3 months;
- **PSA-DT** change between the second and third PSA measurements is 6.2 months.

PSA-DT HOW IS IT CALCULATED?

Between three measurements

- PSA-DT ≤ 10 months: high risk of imminent metastatic disease and death due to prostate cancer.⁷

PSA progression



Calculate PSA-DT:⁶

$$\ln(2) \div \frac{\ln(\text{PSAx}) - \ln(\text{PSA1})}{\text{Time between PSA1 and PSAx}}$$

x = PSA measurement considered for the calculation

- With 3 measurements, the second point (2.5, in this case) is not used in the calculation, but it is important to confirm successive increases;⁶
- PSA-DT change between the first and third PSA measurements is 7.4 months.

PSA-DT REFERENCE VALUES

By time and PSA nadir⁶

- By combining the PSA nadir and the month, we get the value from which **PSA-DT ≤ 10 months**;
- Changes in PSA value above those indicated in the table result in a **PSA-DT ≤ 10 months**.

Values of PSAx that may indicate PSA-DT ≤ 10 months*

PSA1 (ng/mL)	Time between PSA1 and PSAx (months)									
	1	2	3	4	5	6	7	8	9	10
1	1.1	1.1	1.2	1.3	1.4	1.5	1.6	1.8	1.9	2.0
2	2.1	2.3	2.5	2.6	2.8	3.0	3.2	3.5	3.7	4.0
3	3.2	3.4	3.7	4.0	4.3		4.6	4.9	5.2	5.6
4	4.3	4.6	4.9	5.3	5.7		6.1	6.5	7.0	7.5
5	5.4	5.7	6.2	6.6	7.1		7.6	8.1	8.7	9.3
6	6.4	6.9	7.4	7.9	8.5		9.1	9.7	10.4	11.2
7	7.5	8.0	8.6	9.2	9.9		10.6	11.4	12.2	13.1
8	8.6	9.2	9.9	10.5	11.3		12.1	13.0	13.9	14.9
9	9.6	10.3	11.1	11.9	12.8		13.7	14.6	15.7	16.8
10	10.6	11.4	12.2	13.1	14.0		14.9	15.8	16.8	18.0

e.g.: A PSA increase from 2.0 to 3.0 ng/mL or more in **6 months means a PSA-DT ≤ 10 months**

*For the purposes of this primer, some values have been rounded.

PSA-DT REFERENCE VALUES


By time and PSA nadir⁶

- It should be noted that there are standard variations in the time between two measurements, which can be used to indicate whether a patient may have PSA-DT ≤ 10 months.

Values of PSAx that may indicate PSA-DT ≤ 10 months

PSA1 (ng/mL)	Time between PSA1 and PSAx (months)									
	1	2	3	4	5	6	7	8	9	10
1	7%	15%	23%	32%	42%	52%	62%	74%	87%	100%
2	7%	15%	23%	32%	42%	52%	62%	74%	87%	100%
3	7%	15%	23%	32%	42%	52%	62%	74%	87%	100%
4	7%	15%	23%	32%	42%	52%	62%	74%	87%	100%
5	7%	15%	23%	32%	42%	52%	62%	74%	87%	100%
6	7%	15%	23%	32%	42%	52%	62%	74%	87%	100%
7	7%	15%	23%	32%	42%	52%	62%	74%	87%	100%
8	7%	15%	23%	32%	42%	52%	62%	74%	87%	100%
9	7%	15%	23%	32%	42%	52%	62%	74%	87%	100%
10	7%	15%	23%	32%	42%	52%	62%	74%	87%	100%

OR



PSA-DT

REFERENCE VALUES

By time and PSA nadir⁶

- This primer will allow you to easily identify the PSA value that may indicate a **PSA-DT < 10 months**, for different PSA levels.

Odd PSA-DT numbers are on page backs

Even PSA-DT numbers are on page fronts

PSA 3 REFERENCE TABLE FOR PSA-DT \leq 10 MONTHS
By time and PSA nadir⁶

Values of PSA_x that may indicate PSA-DT \leq 10 months*

Time between PSA ₁ and PSA _x (months)												
1	2	3	4	5	6	7	8	9	10	11	12	
1.0	3.2	3.4	3.7	4.0	4.2	4.5	4.9	5.2	5.6	6.0	6.4	6.9
2.0	3.3	3.6	3.8	4.1	4.4	4.7	5.0	5.4	5.8	6.2	6.6	7.1
3.0	3.4	3.7	3.9	4.2	4.5	4.9	5.2	5.6	6.0	6.4	6.9	7.4
4.0	3.5	3.8	4.1	4.4	4.7	5.0	5.4	5.7	6.2	6.6	7.1	7.6
5.0	3.6	3.9	4.2	4.5	4.8	5.2	5.5	5.9	6.3	6.8	7.3	7.8
6.0	3.8	4.0	4.3	4.6	4.9	5.3	5.7	6.1	6.5	7.0	7.5	8.0
7.0	3.9	4.1	4.4	4.8	5.1	5.5	5.8	6.3	6.7	7.2	7.7	8.3
8.0	4.0	4.3	4.6	4.9	5.2	5.6	6.0	6.4	6.9	7.4	7.9	8.5
9.0	4.1	4.4	4.7	5.0	5.4	5.8	6.2	6.6	7.1	7.6	8.1	8.7
10.0	4.2	4.5	4.8	5.1	5.5	5.9	6.3	6.8	7.3	7.8	8.4	9.0
11.0	4.3	4.6	4.9	5.3	5.7	6.1	6.5	7.0	7.5	8.0	8.6	9.2
12.0	4.4	4.7	5.0	5.4	5.8	6.2	6.6	7.1	7.6	8.2	8.8	9.4

PSA 4 REFERENCE TABLE FOR PSA-DT \leq 10 MONTHS
By time and PSA nadir⁶

Values of PSA_x that may indicate PSA-DT \leq 10 months*

Time between PSA ₁ and PSA _x (months)													
1	2	3	4	5	6	7	8	9	10	11	12		
4.0	4.3	4.6	4.9	5.3	5.7	6.1	6.5	6.8	7.0	7.5	8.0	8.6	9.2
4.1	4.4	4.7	5.0	5.4	5.8	6.2	6.7	7.1	7.7	8.2	8.8	9.4	10.0
4.2	4.5	4.8	5.2	5.5	5.9	6.4	6.8	7.3	7.8	8.4	9.0	9.6	10.2
4.3	4.6	4.9	5.3	5.7	6.1	6.5	7.0	7.5	8.0	8.6	9.2	9.9	10.6
4.4	4.7	5.1	5.4	5.8	6.2	6.7	7.1	7.7	8.2	8.8	9.4	10.1	10.8
4.5	4.8	5.2	5.5	5.9	6.4	6.8	7.3	7.8	8.4	9.0	9.6	10.3	11.0
4.6	4.9	5.3	5.7	6.1	6.5	7.0	7.5	8.0	8.6	9.2	9.9	10.6	11.3
4.7	5.0	5.4	5.8	6.2	6.6	7.1	7.6	8.2	8.8	9.4	10.1	10.8	11.5
4.8	5.1	5.5	5.9	6.3	6.8	7.3	7.8	8.4	9.0	9.6	10.3	11.0	11.8
4.9	5.3	5.6	6.0	6.5	6.9	7.4	8.0	8.5	9.1	9.8	10.5	11.3	12.0
5.0	5.4	5.7	6.2	6.6	7.1	7.6	8.1	8.7	9.4	10.0	10.7	11.5	12.2

*For the purposes of this primer, some values have been rounded.

*For the purposes of this primer, some values have been rounded.

For each initial PSA value, the table presents 0.1 increments, up to the next PSA value.

PSA 0

REFERENCE TABLE FOR PSA-DT ≤ 10 MONTHS

By time and PSA nadir⁶

Values of PSAX that may indicate PSA-DT ≤ 10 months*

	Time between PSA1 and PSAX (months)											
	1	2	3	4	5	6	7	8	9	10	11	12
0.0	-	-	-	-	-	-	-	-	-	-	-	-
0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.2	0.2	0.2
0.2	0.2	0.2	0.2	0.3	0.3	0.3	0.3	0.3	0.4	0.4	0.4	0.5
0.3	0.3	0.3	0.4	0.4	0.4	0.5	0.5	0.5	0.6	0.6	0.6	0.7
0.4	0.4	0.5	0.5	0.5	0.6	0.6	0.6	0.7	0.7	0.8	0.9	0.9
0.5	0.5	0.6	0.6	0.7	0.7	0.8	0.8	0.9	0.9	1.0	1.1	1.1
0.6	0.6	0.7	0.7	0.8	0.8	0.9	1.0	1.0	1.1	1.2	1.3	1.4
0.7	0.8	0.8	0.9	0.9	1.0	1.1	1.1	1.2	1.3	1.4	1.5	1.6
0.8	0.9	0.9	1.0	1.1	1.1	1.2	1.3	1.4	1.5	1.6	1.7	1.8
0.9	1.0	1.0	1.1	1.2	1.3	1.4	1.5	1.6	1.7	1.8	1.9	2.1
1.0	1.1	1.1	1.1	1.3	1.4	1.5	1.6	1.7	1.9	2.0	2.1	2.3

*For the purposes of this primer, some values have been rounded.

PSA 1 REFERENCE TABLE FOR PSA-DT ≤ 10 MONTHS

By time and PSA nadir⁶

Values of PSAx that may indicate PSA-DT ≤ 10 months*

	Time between PSA1 and PSAx (months)											
	1	2	3	4	5	6	7	8	9	10	11	12
PSA1 (ng/mL)	1.0	1.1	1.2	1.3	1.4	1.5	1.6	1.7	1.9	2.0	2.1	2.3
1.0	1.1	1.1	1.2	1.3	1.4	1.5	1.6	1.7	1.9	2.0	2.1	2.3
1.1	1.2	1.3	1.4	1.5	1.6	1.7	1.8	1.9	2.1	2.2	2.4	2.5
1.2	1.3	1.4	1.5	1.6	1.7	1.8	1.9	2.1	2.2	2.4	2.6	2.8
1.3	1.4	1.5	1.6	1.7	1.8	2.0	2.1	2.3	2.4	2.6	2.8	3.0
1.4	1.5	1.6	1.7	1.8	2.0	2.1	2.3	2.4	2.6	2.8	3.0	3.2
1.5	1.6	1.7	1.8	2.0	2.1	2.3	2.4	2.6	2.8	3.0	3.2	3.4
1.6	1.7	1.8	2.0	2.1	2.3	2.4	2.6	2.8	3.0	3.2	3.4	3.7
1.7	1.8	2.0	2.1	2.2	2.4	2.6	2.8	3.0	3.2	3.4	3.6	3.9
1.8	1.9	2.1	2.2	2.4	2.5	2.7	2.9	3.1	3.4	3.6	3.9	4.1
1.9	2.0	2.2	2.3	2.5	2.7	2.9	3.1	3.3	3.5	3.8	4.1	4.4
2.0	2.1	2.3	2.5	2.6	2.8	3.0	3.2	3.5	3.7	4.0	4.3	4.6

*For the purposes of this primer, some values have been rounded.

PSA 2 REFERENCE TABLE FOR PSA-DT ≤ 10 MONTHS

By time and PSA nadir⁶

2

Values of PSAx that may indicate PSA-DT ≤ 10 months*

		Time between PSA1 and PSAx (months)											
		1	2	3	4	5	6	7	8	9	10	11	12
PSA1 (ng/mL)	2.0	2.1	2.3	2.5	2.6	2.8	3.0	3.2	3.5	3.7	4.0	4.3	4.6
	2.1	2.3	2.4	2.6	2.8	3.0	3.2	3.4	3.7	3.9	4.2	4.5	4.8
	2.2	2.4	2.5	2.7	2.9	3.1	3.3	3.6	3.8	4.1	4.4	4.7	5.1
	2.3	2.5	2.6	2.8	3.0	3.3	3.5	3.7	4.0	4.3	4.6	4.9	5.3
	2.4	2.6	2.8	3.0	3.2	3.4	3.6	3.9	4.2	4.5	4.8	5.1	5.5
	2.5	2.7	2.9	3.1	3.3	3.5	3.8	4.1	4.4	4.7	5.0	5.4	5.7
	2.6	2.8	3.0	3.2	3.4	3.7	3.9	4.2	4.5	4.9	5.2	5.6	6.0
	2.7	2.9	3.1	3.3	3.6	3.8	4.1	4.4	4.7	5.0	5.4	5.8	6.2
	2.8	3.0	3.2	3.4	3.7	4.0	4.2	4.5	4.9	5.2	5.6	6.0	6.4
	2.9	3.1	3.3	3.6	3.8	4.1	4.4	4.7	5.0	5.4	5.8	6.2	6.7
	3.0	3.2	3.4	3.7	4.0	4.2	4.5	4.9	5.2	5.6	6.0	6.4	6.9

*For the purposes of this primer, some values have been rounded.

Values of PSAx that may indicate PSA-DT ≤ 10 months*

	Time between PSA1 and PSAx (months)												
	1	2	3	4	5	6	7	8	9	10	11	12	
PSA1 (ng/mL)	3.0	3.2	3.4	3.7	4.0	4.2	4.5	4.9	5.2	5.6	6.0	6.4	6.9
3.1	3.3	3.6	3.8	4.1	4.4	4.7	5.0	5.4	5.8	6.2	6.6	7.1	
3.2	3.4	3.7	3.9	4.2	4.5	4.9	5.2	5.6	6.0	6.4	6.9	7.4	
3.3	3.5	3.8	4.1	4.4	4.7	5.0	5.4	5.7	6.2	6.6	7.1	7.6	
3.4	3.6	3.9	4.2	4.5	4.8	5.2	5.5	5.9	6.3	6.8	7.3	7.8	
3.5	3.8	4.0	4.3	4.6	4.9	5.3	5.7	6.1	6.5	7.0	7.5	8.0	
3.6	3.9	4.1	4.4	4.8	5.1	5.5	5.8	6.3	6.7	7.2	7.7	8.3	
3.7	4.0	4.3	4.6	4.9	5.2	5.6	6.0	6.4	6.9	7.4	7.9	8.5	
3.8	4.1	4.4	4.7	5.0	5.4	5.8	6.2	6.6	7.1	7.6	8.1	8.7	
3.9	4.2	4.5	4.8	5.1	5.5	5.9	6.3	6.8	7.3	7.8	8.4	9.0	
4.0	4.3	4.6	4.9	5.3	5.7	6.1	6.5	7.0	7.5	8.0	8.6	9.2	

*For the purposes of this primer, some values have been rounded.

PSA 4 REFERENCE TABLE FOR PSA-DT ≤ 10 MONTHS

By time and PSA nadir⁶

4

Values of PSAx that may indicate PSA-DT ≤ 10 months*

PSA1 (ng/mL)	Time between PSA1 and PSAx (months)											
	1	2	3	4	5	6	7	8	9	10	11	12
4.0	4.3	4.6	4.9	5.3	5.7	6.1	6.5	7.0	7.5	8.0	8.6	9.2
4.1	4.4	4.7	5.0	5.4	5.8	6.2	6.7	7.1	7.7	8.2	8.8	9.4
4.2	4.5	4.8	5.2	5.5	5.9	6.4	6.8	7.3	7.8	8.4	9.0	9.6
4.3	4.6	4.9	5.3	5.7	6.1	6.5	7.0	7.5	8.0	8.6	9.2	9.9
4.4	4.7	5.1	5.4	5.8	6.2	6.7	7.1	7.7	8.2	8.8	9.4	10.1
4.5	4.8	5.2	5.5	5.9	6.4	6.8	7.3	7.8	8.4	9.0	9.6	10.3
4.6	4.9	5.3	5.7	6.1	6.5	7.0	7.5	8.0	8.6	9.2	9.9	10.6
4.7	5.0	5.4	5.8	6.2	6.6	7.1	7.6	8.2	8.8	8.4	10.1	10.8
4.8	5.1	5.5	5.9	6.3	6.8	7.3	7.8	8.4	9.0	9.6	10.3	11.0
4.9	5.3	5.6	6.0	6.5	6.9	7.4	8.0	8.5	9.1	9.8	10.5	11.3
5.0	5.4	5.7	6.2	6.6	7.1	7.6	8.1	8.7	9.4	10.0	10.7	11.5

*For the purposes of this primer, some values have been rounded.

PSA 5

REFERENCE TABLE FOR PSA-DT ≤ 10 MONTHS

By time and PSA nadir⁶

5

Values of PSAx that may indicate PSA-DT ≤ 10 months*

PSA1 (ng/mL)	Time between PSA1 and PSAx (months)											
	1	2	3	4	5	6	7	8	9	10	11	12
5.0	5.4	5.7	6.2	6.6	7.1	7.6	8.1	8.7	9.3	10.0	10.7	11.5
5.1	5.5	5.9	6.3	6.7	7.2	7.7	8.3	7.9	9.5	10.2	10.9	11.7
5.2	5.6	6.0	6.4	6.9	7.4	7.9	8.4	9.1	9.7	10.4	11.1	11.9
5.3	5.7	6.1	6.5	7.0	7.5	8.0	8.6	9.2	9.9	10.6	11.4	12.2
5.4	5.8	6.2	6.6	7.1	7.6	8.2	8.8	9.4	10.1	10.8	11.6	12.4
5.5	5.9	6.3	6.8	7.3	7.8	8.3	8.9	9.6	10.3	11.0	11.8	12.6
5.6	6.0	6.4	6.9	7.4	7.9	8.5	9.1	9.8	10.4	11.2	12.0	12.9
5.7	6.1	6.5	7.0	7.5	8.1	8.6	9.3	9.9	10.6	11.4	12.2	13.1
5.8	6.2	6.7	7.1	7.7	8.2	8.8	9.4	10.1	10.8	11.6	12.4	13.3
5.9	6.3	6.8	7.3	7.8	8.3	8.9	9.6	10.3	11.0	11.8	12.6	13.6
6.0	6.4	6.9	7.4	7.9	8.5	9.1	9.7	10.4	11.2	12.0	12.9	13.8

*For the purposes of this primer, some values have been rounded.

PSA 6 REFERENCE TABLE FOR PSA-DT ≤ 10 MONTHS

By time and PSA nadir⁶

Values of PSAx that may indicate PSA-DT ≤ 10 months*

PSA1 (ng/mL)	Time between PSA1 and PSAx (months)											
	1	2	3	4	5	6	7	8	9	10	11	12
6.0	6.4	6.9	7.4	7.9	8.5	9.1	9.7	10.4	11.2	12.0	12.9	13.8
6.1	6.5	7.0	7.5	8.0	8.6	9.2	9.9	10.6	11.4	12.2	13.1	14.0
6.2	6.6	7.1	7.6	8.2	8.8	9.4	10.1	10.8	11.6	12.4	13.3	14.2
6.3	6.8	7.2	7.8	8.3	8.9	9.5	10.2	11.0	11.8	12.6	13.5	14.5
6.4	6.9	7.4	7.9	8.4	9.1	9.7	10.4	11.1	11.9	12.8	13.7	14.7
6.5	7.0	7.5	8.0	8.6	9.2	9.9	10.6	11.3	12.1	13.0	13.9	14.9
6.6	7.1	7.6	8.1	8.7	9.3	10.0	10.7	11.5	12.3	13.2	14.1	15.2
6.7	7.2	7.7	8.2	8.8	9.5	10.2	10.9	11.7	12.5	13.4	14.4	15.4
6.8	7.3	7.8	8.4	9.0	9.6	10.3	11.0	11.8	12.7	13.6	14.6	15.6
6.9	7.4	7.9	8.5	9.1	9.8	10.5	11.2	12.0	12.9	13.8	14.8	15.9
7.0	7.5	8.0	8.6	9.2	9.9	10.6	11.4	12.2	13.1	14.0	15.0	16.1

*For the purposes of this primer, some values have been rounded.

PSA 7

REFERENCE TABLE FOR PSA-DT ≤ 10 MONTHS

By time and PSA nadir⁶

Values of PSAx that may indicate PSA-DT ≤ 10 months*

PSA1 (ng/mL)	Time between PSA1 and PSAx (months)											
	1	2	3	4	5	6	7	8	9	10	11	12
7.0	7.5	8.0	8.6	9.2	9.9	10.6	11.4	12.2	13.1	14.0	15.0	16.1
7.1	7.6	8.2	8.7	9.4	10.0	10.8	11.5	12.4	13.2	14.2	15.2	16.3
7.2	7.7	8.3	8.9	9.5	10.2	10.9	11.7	12.5	13.4	14.4	15.4	16.5
7.3	7.8	8.4	9.0	9.6	10.3	11.1	11.9	12.7	13.6	14.6	15.6	16.8
7.4	7.9	8.5	9.1	9.8	10.5	11.2	12.0	12.9	13.8	14.8	15.9	17.0
7.5	8.0	8.6	9.2	9.9	10.6	11.4	12.2	13.1	14.0	15.0	16.1	17.2
7.6	8.1	8.7	9.4	10.0	10.7	11.5	12.3	13.2	14.2	15.2	16.3	17.5
7.7	8.3	8.8	9.5	10.2	10.9	11.7	12.5	13.4	14.4	15.4	16.5	17.7
7.8	8.4	9.0	9.6	10.3	11.0	11.8	12.7	13.6	14.6	15.6	16.7	17.9
7.9	8.5	9.1	9.7	10.4	11.2	12.0	12.8	13.8	14.7	15.8	16.9	18.1
8.0	8.6	9.2	9.8	10.6	11.3	12.1	13.0	13.9	14.9	16.0	17.1	18.4

*For the purposes of this primer, some values have been rounded.

PSA 8 REFERENCE TABLE FOR PSA-DT ≤ 10 MONTHS

By time and PSA nadir⁶

Values of PSAx that may indicate PSA-DT ≤ 10 months*

PSA1 (ng/mL)	Time between PSA1 and PSAx (months)											
	1	2	3	4	5	6	7	8	9	10	11	12
8.0	8.6	9.2	9.8	10.6	11.3	12.1	13.0	13.9	14.9	16.0	17.1	18.4
8.1	8.7	9.3	10.0	10.7	11.5	12.3	13.2	14.1	15.1	16.2	17.4	18.6
8.2	8.8	9.4	10.1	10.8	11.6	12.4	13.3	14.3	15.3	16.4	17.6	18.8
8.3	8.9	9.5	10.2	11.0	11.7	12.6	13.5	14.5	15.5	16.6	17.8	19.1
8.4	9.0	9.6	10.3	11.1	11.9	12.7	13.6	14.6	15.7	16.8	18.0	19.3
8.5	9.1	9.8	10.5	11.2	12.0	12.9	13.8	14.8	15.9	17.0	18.2	19.5
8.6	9.2	8.8	10.6	11.3	12.2	13.0	14.0	15.0	16.0	17.2	18.4	19.8
8.7	9.3	10.0	10.7	11.5	12.3	13.2	14.1	15.1	16.2	17.4	18.6	20.0
8.8	9.4	10.1	10.8	11.6	12.4	13.3	14.3	15.3	16.4	17.6	18.9	20.2
8.9	9.5	10.2	11.0	11.7	12.6	13.5	14.5	15.5	16.6	17.8	19.1	20.4
9.0	9.6	10.3	11.1	11.9	12.7	13.6	14.6	15.7	16.8	18.0	19.3	20.7

*For the purposes of this primer, some values have been rounded.

PSA 9

REFERENCE TABLE FOR PSA-DT ≤ 10 MONTHS

By time and PSA nadir⁶

Values of PSAx that may indicate PSA-DT ≤ 10 months*

PSA1 (ng/mL)	Time between PSA1 and PSAx (months)											
	1	2	3	4	5	6	7	8	9	10	11	12
9.0	9.6	10.3	11.1	11.9	12.7	13.6	14.6	15.7	16.8	18.0	19.3	20.7
9.1	9.8	10.5	11.2	12.0	12.9	13.8	14.8	15.8	17.0	18.2	19.5	20.9
9.2	9.9	10.6	11.3	12.1	13.0	13.9	14.9	16.0	17.2	18.4	19.7	21.1
9.3	10.0	10.7	11.4	12.3	13.2	14.1	15.1	16.2	17.4	18.6	19.9	21.4
9.4	10.1	10.8	11.6	12.4	13.3	14.2	15.3	16.4	17.5	18.8	20.1	21.6
9.5	10.2	10.9	11.7	12.5	13.4	14.4	15.4	16.5	17.7	19.0	20.4	21.8
9.6	10.3	11.0	11.8	12.7	13.6	14.6	15.6	16.7	17.9	19.2	20.6	22.1
9.7	10.4	11.1	11.9	12.8	13.7	14.7	15.8	16.9	18.1	19.4	20.8	22.3
9.8	10.5	11.3	12.1	12.9	13.9	14.9	15.9	17.1	18.3	19.6	21.0	22.5
9.9	10.6	11.4	12.2	13.1	14.0	15.0	16.1	17.2	18.5	19.8	21.2	22.7
10.0	10.7	11.5	12.3	13.2	14.1	15.2	16.2	17.4	18.7	20.0	21.4	23.0

*For the purposes of this primer, some values have been rounded.

PSA 10

REFERENCE TABLE FOR PSA-DT ≤ 10 MONTHS

By time and PSA nadir⁶

Values of PSA_x that may indicate PSA-DT ≤ 10 months*

PSA ₁ (ng/mL)	Time between PSA ₁ and PSA _x (months)											
	1	2	3	4	5	6	7	8	9	10	11	12
10.0	10.7	11.5	12.3	13.2	14.1	15.2	16.2	17.4	18.7	20.0	21.4	23.0
10.1	10.8	11.6	12.4	13.3	14.3	15.3	16.4	17.6	18.8	20.2	21.6	23.2
10.2	10.9	11.7	12.6	13.5	14.4	15.5	16.6	17.8	19.0	20.4	21.9	23.4
10.3	11.0	11.8	12.7	13.6	14.6	15.6	16.7	17.9	19.2	20.6	22.1	23.7
10.4	11.1	11.9	12.8	13.7	14.7	15.8	16.9	18.1	19.4	20.8	22.3	23.9
10.5	11.3	12.1	12.9	13.9	14.8	15.9	17.1	18.3	19.6	21.0	22.5	24.1
10.6	11.4	12.2	13.1	14.0	15.0	16.1	17.2	18.5	19.8	21.2	22.7	24.4
10.7	11.5	12.3	13.2	14.1	15.1	16.2	17.4	18.6	20.0	21.4	22.9	24.6
10.8	11.6	12.4	13.3	14.3	15.3	16.4	17.5	18.8	20.2	21.6	23.2	24.8
10.9	11.7	12.5	13.4	14.4	15.4	16.5	17.7	19.0	20.3	21.8	23.4	25.0
11.0	11.8	12.6	13.5	14.5	15.6	16.7	17.9	19.2	20.5	22.0	23.6	25.3

*For the purposes of this primer, some values have been rounded.

PSA 11

REFERENCE TABLE FOR PSA-DT ≤ 10 MONTHS

By time and PSA nadir⁶

Values of PSAx that may indicate PSA-DT ≤ 10 months*

PSA1 (ng/mL)	Time between PSA1 and PSAx (months)											
	1	2	3	4	5	6	7	8	9	10	11	12
11.0	11.8	12.6	13.5	14.5	15.6	16.7	17.9	19.2	20.5	22.0	23.6	25.3
11.1	11.9	12.8	13.7	14.6	15.7	16.8	18.0	19.3	20.7	22.2	23.8	25.5
11.2	12.0	12.9	13.8	14.8	15.8	17.0	18.2	19.5	20.9	22.4	24.0	25.7
11.3	12.1	13.0	13.9	14.9	16.0	17.1	18.4	19.7	21.1	22.6	24.2	26.0
11.4	12.2	13.1	14.0	15.0	16.1	17.3	18.5	19.8	21.3	22.8	24.4	26.2
11.5	12.3	13.2	14.2	15.2	16.3	17.4	18.7	20.0	21.5	23.0	24.7	26.4
11.6	12.4	13.3	14.3	15.3	16.4	17.6	18.8	20.2	21.6	23.2	24.9	26.6
11.7	12.5	13.4	14.4	15.4	16.5	17.7	19.0	20.4	21.8	23.4	25.1	26.9
11.8	12.6	13.6	14.5	15.6	16.7	17.9	19.2	20.5	22.0	23.6	25.3	27.1
11.9	12.8	13.7	14.7	15.7	16.8	18.0	19.3	20.7	22.2	23.8	25.5	27.3
12.0	12.9	13.8	14.8	15.8	17.0	18.2	19.5	20.9	22.4	24.0	25.7	27.6

*For the purposes of this primer, some values have been rounded.

PSA 12 REFERENCE TABLE FOR PSA-DT ≤ 10 MONTHS

By time and PSA nadir⁶

Values of PSAx that may indicate PSA-DT ≤ 10 months*

PSA1 (ng/mL)	Time between PSA1 and PSAx (months)											
	1	2	3	4	5	6	7	8	9	10	11	12
12.0	12.9	13.8	14.8	15.8	17.0	18.2	19.5	20.9	22.4	24.0	25.7	27.6
12.1	13.0	13.9	14.9	16.0	17.1	18.3	19.7	21.1	22.6	24.2	25.9	27.8
12.2	13.1	14.0	15.0	16.1	17.3	18.5	19.8	21.2	22.8	24.4	26.2	28.0
12.3	13.2	14.1	15.1	16.2	17.4	18.6	20.0	21.4	23.0	24.6	26.4	28.3
12.4	13.3	14.2	15.3	16.4	17.5	18.8	20.1	21.6	23.1	24.8	26.6	28.5
12.5	13.4	14.4	15.4	16.5	17.7	18.9	20.3	21.8	23.3	25.0	26.8	28.7
12.7	13.5	14.5	15.5	16.6	17.8	19.1	20.5	21.9	23.5	25.2	27.0	28.9
12.7	13.6	14.6	15.6	16.8	18.0	19.2	20.6	22.1	23.7	25.4	27.2	29.2
12.8	13.7	14.7	15.8	16.9	18.1	19.4	20.8	22.3	23.9	25.6	27.4	29.4
12.9	13.8	14.8	15.9	17.0	18.2	19.6	21.0	22.5	24.1	25.8	27.7	29.6
13.0	13.9	14.9	16.0	17.2	18.4	19.7	21.1	22.6	24.3	26.0	27.9	29.9

*For the purposes of this primer, some values have been rounded.

PSA 13

REFERENCE TABLE FOR PSA-DT ≤ 10 MONTHS

By time and PSA nadir⁶

Values of PSAx that may indicate PSA-DT ≤ 10 months*

PSA1 (ng/mL)	Time between PSA1 and PSAx (months)											
	1	2	3	4	5	6	7	8	9	10	11	12
13.0	13.9	14.9	16.0	17.2	18.4	19.7	21.1	22.6	24.3	26.0	27.9	29.9
13.1	14.0	15.0	16.1	17.3	18.5	19.9	21.3	22.8	24.4	26.2	28.1	30.1
13.2	14.1	15.2	16.3	17.4	18.7	20.0	21.4	23.0	24.6	26.4	28.3	30.3
13.3	14.3	15.3	16.4	17.5	18.8	20.2	21.6	23.2	24.8	26.6	28.5	30.6
13.4	14.4	15.4	16.5	17.7	19.0	20.3	21.8	23.3	25.0	26.8	28.7	30.8
13.5	14.5	15.5	16.6	17.8	19.1	20.5	21.9	23.5	25.2	27.0	28.9	31.0
13.6	14.6	15.6	16.7	17.9	19.2	20.6	22.1	23.7	25.4	27.2	29.2	31.2
13.7	14.7	15.7	16.9	18.1	19.4	20.8	22.3	23.9	25.6	27.4	29.4	31.5
13.8	14.8	15.9	17.0	18.2	19.5	20.9	22.4	24.0	25.8	27.6	29.6	31.7
13.9	14.9	16.0	17.1	18.3	19.7	21.1	22.6	24.2	25.9	27.8	29.8	31.9
14.0	15.0	16.1	17.2	18.5	19.8	21.2	22.7	24.4	26.1	28.0	30.0	32.2

*For the purposes of this primer, some values have been rounded.

PSA 14 REFERENCE TABLE FOR PSA-DT ≤ 10 MONTHS

By time and PSA nadir⁶

Values of PSAX that may indicate PSA-DT ≤ 10 months*

PSA1 (ng/mL)	Time between PSA1 and PSAX (months)											
	1	2	3	4	5	6	7	8	9	10	11	12
14.0	15.0	16.1	17.2	18.5	19.8	21.2	22.7	24.4	26.1	28.0	30.0	32.2
14.1	15.1	16.2	17.4	18.6	19.9	21.4	22.9	24.5	26.3	28.2	30.2	32.4
14.2	15.2	16.3	17.5	18.7	20.1	21.5	23.1	24.7	26.5	28.4	30.4	32.6
14.3	15.3	16.4	17.6	18.9	20.2	21.7	23.2	24.9	26.7	28.6	30.7	32.9
14.4	15.4	16.5	17.7	19.0	20.4	21.8	23.4	25.1	26.9	28.8	30.9	33.1
14.5	15.5	16.7	17.9	19.1	20.5	22.0	23.6	25.2	27.1	29.0	31.1	33.3
14.6	15.6	16.8	18.0	19.3	20.6	22.1	23.7	25.4	27.2	29.2	31.3	33.5
14.7	15.8	16.9	18.1	19.4	20.8	22.3	23.9	25.6	27.4	29.4	31.5	33.8
14.8	15.9	17.0	18.2	19.5	20.9	22.4	24.0	25.8	27.6	29.6	31.7	34.0
14.9	16.0	17.1	18.3	19.7	21.1	22.6	24.2	25.9	27.8	29.8	31.9	34.2
15.0	16.1	17.2	18.5	19.8	21.2	22.7	24.4	26.1	28.0	30.0	32.2	34.5

*For the purposes of this primer, some values have been rounded.

PSA 15

REFERENCE TABLE FOR PSA-DT ≤ 10 MONTHS

By time and PSA nadir⁶

Values of PSAx that may indicate PSA-DT ≤ 10 months*

PSA1 (ng/mL)	Time between PSA1 and PSAx (months)											
	1	2	3	4	5	6	7	8	9	10	11	12
15.0	16.1	17.2	18.5	19.8	21.2	22.7	24.4	26.1	28.0	30.0	32.3	34.5
15.1	16.2	17.3	18.6	19.9	21.4	22.9	24.5	26.3	28.2	30.2	32.4	34.7
15.2	16.3	17.5	18.7	20.1	21.5	23.0	24.7	26.5	28.4	30.4	32.6	34.9
15.3	16.4	17.6	18.8	20.2	21.6	23.2	24.9	26.6	28.6	30.6	32.8	35.2
15.4	16.5	17.7	19.0	20.3	21.8	23.3	25.0	26.8	28.7	30.8	33.0	35.4
15.5	16.6	17.8	19.1	20.5	21.9	23.5	25.2	27.0	28.9	31.0	33.2	35.6
15.6	16.7	17.9	19.2	20.6	22.1	23.6	25.3	27.2	29.1	31.2	33.4	35.8
15.7	16.8	18.0	19.3	20.7	22.2	23.8	25.5	27.3	29.3	31.4	33.7	36.1
15.8	16.9	18.1	19.5	20.8	22.3	23.9	25.7	27.5	29.5	31.6	33.9	36.3
15.9	17.0	18.3	19.6	21.0	22.5	24.1	25.8	27.7	29.7	31.8	34.1	36.5
16.0	17.1	18.4	19.7	21.1	22.6	24.3	26.0	27.9	29.9	32.0	34.3	36.8

*For the purposes of this primer, some values have been rounded.

PSA 16

REFERENCE TABLE FOR PSA-DT ≤ 10 MONTHS

By time and PSA nadir⁶

Values of PSAx that may indicate PSA-DT ≤ 10 months*

PSA1 (ng/mL)	Time between PSA1 and PSAx (months)											
	1	2	3	4	5	6	7	8	9	10	11	12
16.0	17.1	18.4	19.7	21.1	22.6	24.3	26.0	27.9	29.9	32.0	34.3	36.8
16.1	17.3	18.5	19.8	21.2	22.8	24.4	26.2	28.0	30.0	32.2	34.5	37.0
16.2	17.4	18.6	19.9	21.4	22.9	24.6	26.3	28.2	30.2	32.4	34.7	37.2
16.3	17.5	18.7	20.1	21.5	23.1	24.7	26.5	28.4	30.4	32.6	34.9	37.4
16.4	17.6	18.8	20.2	21.6	23.2	24.9	26.6	28.6	30.6	32.8	35.2	37.7
16.5	17.7	19.0	20.3	21.8	23.3	25.0	26.8	28.7	30.8	33.0	35.4	37.9
16.6	17.8	19.1	20.4	21.9	23.5	25.2	27.0	28.9	31.0	33.2	35.6	38.1
16.7	17.9	19.2	20.6	22.0	23.6	25.3	27.1	29.1	31.2	33.4	35.8	38.4
16.8	18.0	19.3	20.7	22.2	23.8	25.5	27.3	29.3	31.3	33.6	36.0	38.6
16.9	18.1	19.4	20.8	22.3	23.9	25.6	27.5	29.4	31.5	33.8	36.2	38.8
17.0	18.2	19.5	20.9	22.4	24.0	25.8	27.6	29.6	31.7	34.0	36.4	39.1

*For the purposes of this primer, some values have been rounded.

By time and PSA nadir⁶**Values of PSAx that may indicate PSA-DT ≤ 10 months***

	Time between PSA1 and PSAx (months)											
	1	2	3	4	5	6	7	8	9	10	11	12
17.0	18.2	19.5	20.9	22.4	24.0	25.8	27.6	29.6	31.7	34.0	36.4	39.1
17.1	18.3	19.6	21.1	22.6	24.2	25.9	27.8	29.8	31.9	34.2	36.7	39.3
17.2	18.4	19.8	21.2	22.7	24.3	26.1	27.9	29.9	32.1	34.4	36.9	39.5
17.3	18.5	19.9	21.3	22.8	24.5	26.2	28.1	30.1	32.3	34.6	37.1	39.7
17.4	18.6	20.0	21.4	23.0	24.6	26.4	28.3	30.3	32.5	34.8	37.3	40.0
17.5	18.8	20.1	21.5	23.1	24.7	26.5	28.4	30.5	32.7	35.0	37.5	40.2
17.6	18.9	20.2	21.7	23.2	24.9	26.7	28.6	30.6	32.8	35.2	37.7	40.4
17.7	19.0	20.3	21.8	23.4	25.0	26.8	28.8	30.8	33.0	35.4	37.9	40.7
17.8	19.1	20.4	21.9	23.5	25.2	27.0	28.9	31.0	33.2	35.6	38.2	40.9
17.9	19.2	20.6	22.0	23.6	25.3	27.1	29.1	31.2	33.4	35.8	38.4	41.1
18.0	19.3	20.7	22.2	23.8	25.5	27.3	29.2	31.3	33.6	36.0	38.6	41.4

*For the purposes of this primer, some values have been rounded.

PSA 18 REFERENCE TABLE FOR PSA-DT ≤ 10 MONTHS

By time and PSA nadir⁶

Values of PSAx that may indicate PSA-DT ≤ 10 months*

PSA1 (ng/mL)	Time between PSA1 and PSAx (months)											
	1	2	3	4	5	6	7	8	9	10	11	12
18.0	19.3	20.7	22.2	23.8	25.5	27.3	29.2	31.3	33.6	36.0	38.6	41.4
18.1	19.4	20.8	22.3	23.9	25.6	27.4	29.4	31.5	33.8	36.2	38.8	41.6
18.2	19.5	20.9	22.4	24.0	25.7	27.6	29.6	31.7	34.0	36.4	39.0	31.8
18.3	19.6	21.0	22.5	24.1	25.9	27.7	29.7	31.9	34.1	36.6	39.2	42.0
18.4	19.7	21.1	22.7	24.3	26.0	27.9	29.9	32.0	34.3	36.8	39.4	42.3
18.5	19.8	21.3	22.8	24.4	26.2	28.0	30.1	32.2	34.5	37.0	39.7	42.5
18.6	19.9	21.4	22.9	24.5	26.3	28.2	30.2	32.4	34.7	37.2	39.9	42.7
18.7	20.0	21.5	23.0	24.7	26.4	28.3	30.4	32.6	34.9	37.4	40.1	43.0
18.8	20.1	21.6	23.1	24.8	26.6	28.5	30.5	32.7	35.1	37.6	40.3	43.2
18.9	20.3	21.7	23.3	24.9	26.7	28.6	30.7	32.9	35.3	37.8	40.5	43.4
19.0	20.4	21.8	23.4	25.1	26.9	28.8	30.9	33.1	35.5	38.0	40.7	43.7

*For the purposes of this primer, some values have been rounded.

By time and PSA nadir⁶**Values of PSAx that may indicate PSA-DT ≤ 10 months***

	Time between PSA1 and PSAx (months)												
	1	2	3	4	5	6	7	8	9	10	11	12	
PSA1 (ng/mL)	19.0	20.4	21.8	23.4	25.1	26.9	28.8	30.9	33.1	35.5	38.0	40.7	43.7
	19.1	20.5	21.9	23.5	25.2	27.0	29.0	31.0	33.3	35.6	38.2	40.9	43.9
	19.2	20.6	22.1	23.6	25.3	27.2	29.1	31.2	33.4	35.8	38.4	41.2	44.1
	19.3	20.7	22.2	23.8	25.5	27.3	29.3	31.4	33.6	36.0	38.6	41.4	44.3
	19.4	20.8	22.3	23.9	25.6	27.4	29.4	31.5	33.8	36.2	38.8	41.6	44.6
	19.5	20.9	22.4	24.0	25.7	27.6	29.6	31.7	34.0	36.4	39.0	41.8	44.8
	19.6	21.0	22.5	24.1	25.9	27.7	29.7	31.8	34.1	36.6	39.2	42.0	45.0
	19.7	21.1	22.6	24.3	26.0	27.9	29.9	32.0	34.3	36.8	39.4	42.2	45.3
	19.8	21.2	22.7	24.4	26.1	28.0	30.0	32.2	34.5	36.9	39.6	42.4	45.5
	19.9	21.3	22.9	24.5	26.3	28.1	30.2	32.3	34.6	37.1	39.8	42.7	45.7
	20.0	21.4	23.0	24.6	26.4	28.3	30.3	32.5	34.8	37.3	40.0	42.9	45.9

*For the purposes of this primer, some values have been rounded.

PSA 20

REFERENCE TABLE FOR PSA-DT ≤ 10 MONTHS

By time and PSA nadir⁶

Values of PSAx that may indicate PSA-DT ≤ 10 months*

PSA1 (ng/mL)	Time between PSA1 and PSAx (months)											
	1	2	3	4	5	6	7	8	9	10	11	12
20.0	21.4	23.0	24.6	26.4	28.3	30.3	32.5	34.8	37.3	40.0	42.9	45.9
20.1	21.5	23.1	24.7	26.5	28.4	30.5	32.7	35.0	37.5	40.2	43.1	46.2
20.2	21.6	23.2	24.9	26.7	28.6	30.6	32.8	35.2	37.7	40.4	43.3	46.4
20.3	21.8	23.3	25.0	26.8	28.7	30.8	33.0	35.3	37.9	40.6	43.5	46.6
20.4	21.9	23.4	25.1	26.9	28.8	30.9	33.1	35.5	38.1	40.8	43.7	46.9
20.5	22.0	23.5	25.2	27.0	29.0	31.1	33.3	35.7	38.3	41.0	43.9	47.1
20.6	22.1	23.7	25.4	27.2	29.1	31.2	33.5	359	38.4	41.2	44.2	47.3
20.7	22.2	23.8	25.5	27.3	29.3	31.4	33.6	36.0	38.6	41.4	44.4	47.6
20.8	22.3	23.9	25.6	27.4	29.4	31.5	33.8	36.2	38.8	41.6	44.6	47.8
20.9	22.4	24.0	25.7	27.6	29.6	31.7	34.0	36.4	39.0	41.8	44.8	48.0
21.0	22.5	24.1	25.9	27.7	29.7	31.8	34.1	36.6	39.2	42.0	45.0	48.2

*For the purposes of this primer, some values have been rounded.

PSA-DT REFERENCE VALUES

By time and PSA nadir⁶

Values of PSAx that may indicate PSA-DT ≤ 10 months*

PSA1 (ng/mL)	Time between PSA1 and PSAx (months)									
	1	2	3	4	5	6	7	8	9	10
1	1.1	1.1	1.2	1.3	1.4	1.5	1.6	1.8	1.9	2.0
2	2.1	2.3	2.5	2.6	2.8	3.0	3.2	3.5	3.7	4.0
3	3.1	3.4	3.7	4.0	4.3	4.6	4.9	5.2	5.6	6.0
4	4.3	4.6	4.9	5.3	5.7	6.1	6.5	7.0	7.5	8.0
5	5.4	5.7	6.2	6.6	7.1	7.6	8.1	8.7	9.3	10.0
6	6.4	6.9	7.4	7.9	8.5	9.1	9.7	10.4	11.2	12.0
7	7.5	8.0	8.6	9.2	9.9	10.6	11.4	12.2	13.1	14.0
8	8.6	9.2	9.9	10.5	11.3	12.1	13.0	13.9	14.9	16.0
9	9.6	10.3	11.1	11.9	12.8	13.7	14.6	15.7	16.8	18.0

*For the purposes of this primer, some values have been rounded.

PSA-DT REFERENCES

1. Mottet N, et al. EAU - EANM - ESTRO - ESUR - SIOG Guidelines on Prostate Cancer. European Association of Urology; March 2022. 112-113.
2. Schaeffer E, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Prostate Cancer Version 3. 2022. National Comprehensive Cancer Network 2022. [Published in January 10, 2022].
3. Vickers AJ, et al. PSA Velocity and Doubling Time in Diagnosis and Prognosis of Prostate Cancer. Br J Med Surg Urol. 2012 Jul 1;5(4):162-168.
4. Smith MR, et al. Denosumab and Bone Metastasis-Free Survival in Men With Nonmetastatic Castration Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time. J Clin Oncol. 2013;31:3800–6.
5. Arlen PM, et al. Prostate Specific Antigen Working Group - guidelines on prostate specific antigen doubling time. The Journal of Urology. 2008;179(6):2181-6.
6. Pound C R, et al. Natural History of Progression After PSA Elevation Following Radical Prostatectomy. JAMA. 1999;281(17):1591-7.
7. Smith MR, et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018; 378: 1408-1418
8. Lowrance, W. et al. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline Part II. The Journal of Urology. Available at www.auajournals.org/journal/juro, Jan 2021. Vol 205, 22-29. Accessed May 2022

Disclaimers

This material must be used as a support tool for educational purposes by Healthcare Professionals.

This tool is not a medical device. The tool and the information obtained from it must not be used to conduct a diagnosis, nor to indicate or modify a course of treatment.

PSA-DT

What are the criteria for patients with non-metastatic castration-resistant prostate cancer (nmCRPC)?



Prostate cancer under treatment with ADT
(Androgen Deprivation Therapy)⁷



Resistant to Castration^{7,8}
Testosterone levels < 50 ng/dL,
PSA > 2 ng/mL



In biochemical progression:
Increasing PSA^{1,7}



PSA Doubling Time ≤ 10 months⁷



**No evidence of distant metastases
by conventional methods**
(thorax, abdomen, pelvis CTs; bone scintigraphy)^{2,7}

This is a patient education material/tool provided to you by Johnson and Johnson (Philippines), Inc.
This material is for the use of Philippine Healthcare Professionals only.

NP-ERL-2022-001

Production Date: May 2022

Questions or comments?

Email us at Janssendlugsafety_Phil@its.jnj.com

Johnson & Johnson (Philippines), Inc.
Km. 14, Edison Road Merville,
City of Parañaque NCR,
Fourth District Philippines 1700

Johnson & Johnson
(PHILIPPINES), INC.